Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26688874 | 0.78 | CNKSR1 (0.39) | NOS3NOS2GABRPGABRDGABRA1 | |
| SCHEMBL7276820 | 0.74 | CNKSR1 (0.51) | — | |
| SCHEMBL30757482 | 0.74 | CNKSR1 (0.51) | — | |
| SCHEMBL7284590 | 0.72 | NOS3 (0.42) | NOS3NOS2HRH3GABRPGABRD | |
| SCHEMBL9218265 | 0.72 | NOS3 (0.42) | NOS3NOS2HRH3GABRPGABRD | |
| SCHEMBL9495660 | 0.72 | NOS3 (0.42) | NOS3NOS2HRH3GABRPGABRD | |
| SCHEMBL7275085 | 0.71 | PGK1 (0.36) | — | |
| SCHEMBL7286429 | 0.70 | NOS3 (0.38) | NOS3NOS2GABRPGABRDGABRA1 | |
| SCHEMBL7274895 | 0.70 | GABRP (0.44) | NOS3NOS2GABRPGABRDGABRA1 | |
| SCHEMBL27975567 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| CN-101437818-A | Novel Dual Acting Receptor Antagonists (DARA) for AT1 and ETA receptors | TORRENT PHARMACEUTICALS LTD (IN) | 2009-05-20 | — | — | CN | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| EP-0516392-B1 | Naphthyridine derivatives as angiotensin II inhibitors | ASTRAZENECA AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| US-5294620-A | Hypotensive agents or compounds for cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-15 | — | — | US | disclosed |
| WO-1993024501-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024487-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| US-5217976-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0516392-A2 | Naphthyridine derivatives as angiotensin II inhibitors | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | NOS3 540/4885NOS2 499/4885HRH3 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.